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 Background: Modifications to combination antiretroviral drug therapy (CART) regimens can occur for a number of reasons, 
including adverse drug effects. We investigated the frequency of and reasons for antiretroviral drug modifi-
cations (ADM) during the first 3 years after initiation of CART, in a closed cohort of CART-naïve adult patients 
who started treatment in the period 1998–2007 in Croatia.
 Material/Methods: We calculated differential toxicity rates by the Poisson method. In multivariable analysis, we used a discrete-
time regression model for repeated events for the outcome of modification due to drug toxicity.
 Results: Of 321 patients who started CART, median age was 40 years, 19% were women, baseline CD4 was <200 cells/mm3 
in 71%, and viral load was ≥100 000 copies/mL in 69%. Overall, 220 (68.5%) patients had an ADM; 124 (56%) 
of these had ≥1 ADM for toxicity reasons. Only 12.7% of individuals starting CART in the period 1998–2002 and 
39.4% in the period 2003–2007 remained on the same regimen after 3 years. The following toxicities caused 
ADM most often: lipoatrophy (22%), gastrointestinal symptoms (20%), and neuropathy (18%). Only 5% of drug 
changes were due to virologic failure. Female sex (hazard ratio [HR], 2.42 95%; confidence intervals, 1.39–4.24) 
and older age (HR, 1.42 per every 10 years) were associated with toxicity-related ADM in the first 3 months of 
a particular CART regimen, but after 3 months of CART they were not.
 Conclusions: Less toxic and better-tolerated HIV treatment options should be available and used more frequently in Croatia.
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Background
Adverse effects of combination antiretroviral therapy (CART) 
lead to switching or interruption of HIV therapy and also may 
affect adherence to prescribed medications [1–14]. Antiretroviral 
drug modifications (ADM) due to toxicity have been report-
ed to be associated with many factors: demographic charac-
teristics such as female sex [4–6,13,14], age [6,14], ethnicity 
[15,16], genetics [17], HIV disease status [4,6], type of antiret-
roviral therapy [4–6,14], and co-morbidities [5]. It has also been 
reported that toxicity-related ADM are most frequent within 
the first 3 months of CART [7]. The majority of studies, how-
ever, have focused on the first event of ADM [1–3,5–8,14,18].
Croatia is a southeastern European country (population 4.3 
million) with a centralized system of care for HIV since the 
beginning of the epidemic in 1986. This allows us to analyze 
ADM on a country level. Croatia has an individualized ap-
proach for prescribing CART; however, the availability of drugs 
and diagnostics is limited, and drugs have become unavail-
able at times. New drugs are also introduced slowly; for ex-
ample, there is currently no single-tablet antiretroviral drug 
combination available, and the combination of fixed dose te-
nofovir and emtricitabine only became available in June 2010. 
The majority of southeastern European countries have also 
an individualized approach to CART with limited options, and 
currently there are no data concerning both the number of 
antiretroviral drug modifications and the reasons for these 
modifications.
The aim of this study was to investigate the frequency of and 
reasons for ADM, as well as how sex, age, and other risk fac-
tors affect ADM during the first 3 years after initiation of CART. 
We hypothesized that factors associated with drug toxicities 
are different in the early follow-up period (first 3 months of 
CART) compared to the period after 3 months of follow-up on 
a particular CART regimen. We examined a closed cohort of 
antiretroviral-naïve HIV-infected individuals who started CART 
in Croatia in the period 1998–2007 and analyzed all ADM oc-
curring in the first 3 years of CART.
Material and Methods
Setting
Although a recent increase in cases of HIV infection has been 
observed among men who have sex with men (MSM) [19–21], 
Croatia is still considered a country with a low-level epidemic 
[19,20,22]. Health insurance is universal in Croatia and anti-
retroviral drug therapy became available free of charge in April 
1998. An electronic database has been used at the University 
Hospital for Infectious Diseases (UHID) in Zagreb since 1997. 
This database includes all HIV-infected patients under care in 
Croatia, and data on their basic sociodemographic character-
istics, clinical course, and antiretroviral therapy regiments, as 
well as laboratory findings on CD4 cell count and viral load 
measurements are available.
Study population
Antiretroviral-naïve patients who were not under care out-
side Croatia and who started CART between January 1, 1998, 
and December 31, 2007 and who had at least 1-month fol-
low-up were eligible for the study. We included patients old-
er than 18 years and excluded pregnant women. We also ex-
cluded patients in whom CART was initiated during primary 
infection because treatment in primary infection at the time 
of the study was given mainly on a theoretical basis and only 
for a limited time. The study was approved by the Ethics 
Committee of UHID.
Variables
We defined CART as an antiretroviral drug combination that 
was likely to suppress HIV-1 RNA to undetectable levels. These 
initial combinations included 2 nucleoside reverse transcrip-
tase inhibitors (NRTI) in combination with 1 non-nucleoside 
reverse transcriptase inhibitor (NNRTI) or a protease inhibitor 
(PI), or 3 NRTIs. We also included patients who started CART 
with a PI plus NNRTI combination or with 2 PIs, with NRTIs. 
The type of CART in our analysis was categorized into 2NRTI 
plus 1PI, 2NRTI plus 1NNRTI, and other combinations. The 
NRTI backbone was categorized into zidovudine plus lamivu-
dine (ZDV/3TC), stavudine plus lamivudine (D4T/3TC), abaca-
vir plus lamivudine (ABC/3TC), and other.
Treatment modifications included a drug switch or an inter-
ruption. Switch was defined as a change of at least 1 drug, 
where the time between cessation of one drug combination 
and the initiation of another was ≤1 month and interruption 
when all drugs were stopped for >1 month. A switch from indi-
vidual drugs such as ABC and 3TC to the single-pill co-formula-
tion of ABC-3TC was not considered a treatment modification.
We reviewed all records of patients with treatment modifica-
tions and classified causes of treatment modification as tox-
ic effects or intolerance, physician’s choice, patient’s choice, 
treatment failure, availability of drugs, and other reasons. 
Toxic effects or intolerance were categorized as gastrointes-
tinal, hepatic, hypersensitivity, CNS, neuropathy, lipoatrophy, 
lipohypertrophy, and other. Lipoatrophy and lipohypertrophy 
were assessed subjectively if noticed by the patient and con-
firmed by the physician. Virologic suppression was defined as 
achieving a viral load of <400 copies/mL after 12, 24, and 36 
months of CART.
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Statistical methods
We described the baseline characteristics of our patients by 
the median and interquartile range for continuous variables 
and as frequencies for categorical variables. The baseline data 
on patients are presented according to the type of ADM: ADM 
for toxicity reasons, ADM for other reasons, and no ADM. We 
compared data on basic sociodemographic characteristics (age, 
sex, distance from HIV center, urban or rural residence, and 
HIV transmission risks), HIV disease factors (CD4 cell count, 
HIV-1 RNA viral load, and prior or concomitant AIDS), type of 
CART, calendar period of CART initiation, and coinfection with 
hepatitis B or C virus, using the chi-square or Fisher’s exact 
test for categorical variables and the Kruskal-Wallis test for 
continuous variables.
We calculated the follow-up time in several ways. The follow-
up time ended 3 years after CART initiation for patients who 
were on CART at that date. If a patient who stopped all med-
ications did not restart CART before 3 years after CART initia-
tion, the period of follow-up ended with the date of interrup-
tion. Patients who died or were lost to follow-up were followed 
from the date of starting CART until the date of death or date 
of becoming lost to follow-up.
We used Poisson analysis to compute the rate of toxicity, and 
rate ratios and associated 95% confidence intervals (CI) for 
different individual drugs, and compared those according to 
sex. The total number of days on each individual antiretrovi-
ral drug was used as a denominator.
We compared treatment success in patients who had no treat-
ment modification to those who had only a switch type or an 
interruption type of drug modification. It was assessed by the 
frequency of the viral loads less than 400 copies/ml and the 
median absolute CD4 cell count at 12, 24, and 36 months; 
and by the median increase in the CD4 cell count between 
baseline and 12, 24, and 36 months of CART. The nearest CD4 
counts and VL measurements within 3 months of 12, 24, and 
36 months after starting CART were identified and used in 
this analysis. We conducted a generalized estimation equa-
tion model analysis to compare treatment success in the 3 
above-mentioned groups.
The main outcome in our study was a drug treatment modi-
fication because of toxicity or intolerance. The outcome was 
initially divided into 3 categories (no drug modification, mod-
ification due to toxicity or intolerance, and other modifica-
tion). We used discrete-time regression analysis to model 
competing risks and repeated events with a month as the 
interval of time. Thus, when an event occurred, a new ep-
isode (sequence) began, and time was reset according to 
the outcome of the new drug combination. If the new drug 
combination was not modified further, time (in months) was 
reset to 1; otherwise, time was reset according to the number 
of months on treatment with the drug or drug combination 
that was subsequently changed. The expanded file for dis-
crete-time analysis had 10 615 observations. We compared 
modifications due to drug toxicity to no treatment modifi-
cations in a binary model in which we censored the event 
of drug modification due to non-toxic reasons. Crude anal-
ysis was done including the sequence and time of event (in 
months) and 1 fixed or time-varying explanatory variable. 
Fixed explanatory variables were sex, baseline age, HIV trans-
mission group, distance from HIV center (dichotomized at 
160 km), and place of residence (rural vs. urban, based on 
a population level of below or above 40 000 inhabitants), 
clinical AIDS before or concomitant with CART, calendar year 
of CART initiation (1998–2002 vs. 2003–2007) and seropos-
itivity for hepatitis C and positivity for hepatitis B antigen. 
Time-varying covariates were type of CART regimen and CD4 
cell counts. The CD4 cell count in the discrete time model 
was matched with the months of measurements, and miss-
ing data were extrapolated by carrying the last observation 
forward. Covariates with a p<0.25 in crude analysis were 
considered as candidates for inclusion in the multivariable 
model. Sex, age, and antiretroviral drug combinations were 
included in all models. We constructed separate models for 
different follow-up times (0–3 and 3–36 months) on a par-
ticular drug regimen. We estimated a complementary log-
log model, which is a proportional hazards model allowing 
interpretation of coefficients in terms of hazard ratios (HR). 
To assess the proportionality assumption, we examined the 
interaction of time with each independent variable in all our 
models and, if significant (p <0.05), the interaction was kept 
in the model. The dependency among repeated observations 
was accounted for by robust standard errors. The analysis 
was done using the statistical software package SAS version 
9.3.1 (SAS institute Inc, Cary, North Carolina, USA); the level 
of significance was set at 0.05.
Results
Baseline characteristics
A total of 321 treatment-naïve patients who started ART in 
the period 1997 to 2007 were included in our study. The me-
dian age at baseline was 40 years, 19% were female, base-
line CD4 was <200 cells/mm3 in 71%, and viral load was ≥100 
000 copies/mL in 69% of patients. Baseline characteristics ac-
cording to type of ADM are shown in Table 1. At 3 years af-
ter initiation of CART, 274 (85%) individuals were still taking 
CART, 19 (6%) were known to be alive and not taking CART, 
24 (7%) were dead, 2 (1%) had moved, and 2 (1%) were con-
sidered lost to follow-up.
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Drug modifications
A total of 387 ADM were observed. The reasons for ADM were 
toxicity (including intolerance) in 176 (45.5%), physician’s de-
cision in 117 (30.2%), patient’s choice in 37 (9.6%), treat-
ment failure in 19 (4.9%), availability in 36 (9.3%), and mis-
cellaneous in 2 (0.5%). Three hundred sixteen (81.7%) of the 
ADM episodes were switches, and 71 (18.3%) were interrup-
tions. The total follow-up time of persons on CART was 852.4 
years, and the median follow-up time per patient was 3 (IQR, 
2.9-3.0) years. During the 3-year follow-up, there were 50 in-
stances of restarting an interrupted antiretroviral regiment. 
The 387 ADM involved 220 (68.5%) of the 321 patients in our 
study (1.8 ADM per patient); 124 (39%) had ≥1ADM for tox-
icity reasons. Lipoatrophy (22%), gastrointestinal symptoms 
(20%), and neuropathy (18%) were the most common causes 
of toxicity-related ADM.
Of 852.4 years follow-up on CART, patients spent the most 
time on the following drugs or drug combinations: ZDV plus 
3TC (450.1 years, 52.8%, n=212), d4T plus 3TC (193.5 years, 
22.7%, n=162), ABC plus 3TC (132.3 years, 15.5%, n=81), efavi-
renz (EFV) (359.4 years, 42.2%, n=172), nevirapine (NVP) (83.7 
years, 9.8%, n=56), lopinavir (LPV) (241.4 years, 28.3%, n=116), 
Characteristics
Reason for CART modification No CART modification
Toxicity (n=124)* Other (n=96) No (n=101) p- value
Age, years  42.3 (35–50.9)  38.2 (31.5–45.8)  38.1 (30.9–48.9) 0.005
CD4 cell, count/µL  85.0 (31–212)  71.5 (26–228.5)  151.0 (62.0–216.0) 0.027
HIV-1 RNA, log10 copies/mL  5.3 (4.8–5.9)  5.4 (4.9–5.8)  5.3 (4.8–5.7) 0.139
Female gender  33 (26.6)  14 (14.6)  15 (14.9) 0.032
Distance from HIV center <160 km  47 (37.9)  38 (39.6)  56 (55.4) 0.018
Urban place of living  45 (36.3)  25 (26.0)  38 (37.6) 0.166
Prior or concomitant AIDS  49 (39.5)  47 (49.0)  24 (23.8) 0.001
Calendar year of CART initiation    <0.001
 1998–2002  62 (50.0)  45 (46.9)  21 (20.8)  
 2003–2007  62 (50.0)  51 (53.1)  80 (79.2)  
HBsAg positive  4 (3.2)  5 (5.2)  7 (6.9) 0.423
Antibody to HCV  16 (12.9)  13 (13.5)  7 (6.9) 0.254
Mode of transmission    0.379
 MSM  41 (33.1)  39 (40.6)  49 (48.5)  
 Heterosexual  67 (54.0)  43 (44.8)  40 (39.6)  
 Intravenous drug use  8 (6.5)  7 (7.3)  5 (5.0)  
 Other/unknown  8 (6.5)  7 (7.3)  7 (6.9)  
Initial NRT backbone <0.001
 D4T3TC  70 (56.5)  51 (53.1)  16 (15.8)
 ZDV3TC  42 (33.9)  36 (37.5)  79 (78.2)
 Other/none  12 (9.7)  9 (9.4)  6 (5.9)
Type of initial CART    0.149
 2NRTI plus 1PI  65 (52.4)  53 (55.2)  45 (44.6)  
 2NRTI plus NNRTI  53 (42.7)  39 (40.6)  56 (55.4)  
 Other  6 (4.8)  4 (4.2)   
Table 1. Baseline characteristics of 321 individuals according to reason for CART modification.
* 26 of 124 patients had also a modification for other reasons. Values are medians with interquartile ranges or frequencies and 
percentages. CART – combination antiretroviral therapy; HBsAg – hepatits B surface antigen; HCV – hepatitis C virus; MSM – men who 
have sex with men; D4T – stavudine; 3TC – lamivudine; ZDV – zidovudine; NRTI – nucleoside reverse-transcriptase inhibitor; 
PI – protase inhibitor; NNRTI – nonnucleoside reverse-transcriptase inhibitor.
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and indinavir (IND) or indinavir plus ritonavir (IND/r) (146.3 
years, 17.2%, n=84). We calculated the rate of ADM for toxic-
ity reasons per 100 patient-years for each individual drug. As 
expected, d4T was associated with the highest rate of toxic-
ity-ADM. There were also differences in toxicity-related drug 
modifications between males and females (Table 2). Of individ-
ual drugs, ZDV and NVP were more frequently switched or in-
terrupted for toxicity reasons in women than in men (Table 2).
Of 176 drug modifications due to toxicity, 165 (94%) were 
single-drug changes. More frequent single-drug substitu-
tions because of toxicity included d4T (59 events), ZDV (25 
events), IND (25 events), and EFV (24 events). Of 117 drug 
modifications due to physicians’ suggestion, 98 (84%) were 
single-drug changes; the most frequent single-drug chang-
es involved d4T (45 events), IND (17 events), and zalcitabine 
(ddC) (13 events). Drug changes because of patient’s deci-
sion (37 events) were more frequently interruptions (32, 86%) 
and hence involved more than 1 drug 31 times. Changes be-
cause of drug availability occurred 36 times and included sin-
gle-drug substitutions in 27 (75%) instances. Most of those 
changes occurred in 1999 (24 events) and included substitu-
tions for 3TC (16 events).
Factors related to drug toxicity
Results from crude and multivariable discrete time recurrent 
event regression analyses of predictors of ADM are presented 
in Tables 3 and 4. Of the 176 toxicity-related ADM, 55 (31.3%) 
occurred during the first 3 months of a particular CART regi-
men involving 52 patients, and 121 (68.7%) events among 90 
patients occurred after more than 3 months of CART. Female 
sex and older age were associated with toxicity-related drug 
modifications in the first 3 months of a particular CART regi-
ment, but afterwards they were not. As expected, nucleoside 
backbones such as ABC+3TC and ZDV+3TC had an overall lower 
risk of toxicity-related modification; however, this was not the 
case during the first 3 months of therapy on a particular drug 
regimen. Because of concerns about collinearity, the period of 
CART initiation (1998–2002 vs. 2003–2007) was not included 
in the model together with the type of nucleoside backbone. 
When a separate multivariable model was built (including the 
period of study, but not the type of nucleosides) for 3 to 36 
month follow-up, there was a significant interaction of time 
with the period of CART initiation. This suggests that those who 
started CART in the period 1998–2002 had a higher hazard of 
toxicity-related drug modifications at 9 months (HR 1.63, 95% 
CI 1.05–2.51) and later, whereas coefficients of other variables 
in the model remained very similar. Only 12.7% of individu-
als starting CART in the period 1998–2002 were on the same 
regimen after 3 years, whereas this was the case in 39.4% of 
individuals in the period 2003–2007 (Figure 1).
Virologic and immunological outcomes
Virologic efficacy (defined as achieving an HIV-1 RNA load of 
less than 400 copies/mL) was highest among patients with 
no CART changes and lowest among patients with interrup-
tion of CART (Table 5). Immunological responses (defined as 
the increase in the CD4 cell count from baseline and the ab-
solute CD4 cell count) significantly improved between 12 and 
36 months in patients with no CART change and those who 
had only switches, but there was no improvement in patients 
interrupting CART. The increase in CD4 cell count was greater 
 Males Females p-value 
NRTI  
 Zidovudine  5.1 (3.3–8.0)  13.2 (6.9–25.4)  0.019
 Stavudine  32.0 (24.3–42.3)  28.5 (16.5–49.0)  0.703 
 Abacavir  2.7 (0.9–8.2)  2.7 (0.9–8.2)  
 Didanosine  13.9 (5.2–37.1)  22.3 (5.6–89.2)  0.586 
NNRTI  
 Nevirapine  3.0 (0.7–11.9)  24.5 (9.2–65.2)  0.015 
 Efavirenz  6.9 (4.4–10.7)  13.1 (6.8–25.1)  0.111 
PI  
 Indinavir  20.8 (14.0–30.7)  27.4 (17.7–42.4)  0.657 
 Lopinavir  4.7 (2.6–8.8)  9.8 (3.2–30.4)  0.27 
Table 2. Observed toxicity rate of CART modifications of per 100 patient years for selected antiretrovirals according to gender.
Values are rates and 95% confidence intervals. NRT – nucleoside reverse-transcriptase inhibitor; NNRT – nonnucleoside reverse-
transcriptase inhibitor; PI – protase inhibitor.
487
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS] [Index Copernicus]
Perović Mihanović M et al: 
Antiretroviral drug treatment modifications
© Med Sci Monit, 2013; 19: 483-492
PUBLIC HEALTH
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 3.0 Unported License
Months of follow-up
0 to 3 3 to 36
p-value Crude HR (95% CI)
Gender 0.001 0.300
 Female vs. male 2.58 (1.50–4.45) 1.3 (0.79–2.16)
Age, per 10-year increase <0.001 0.180
 Age 1.47 (1.2–1.81) 1.12 (0.95–1.32)
Distance from HIV center 0.659 0.05
 <160 km vs. ≥160 km 0.89 (0.53–1.5) 0.63 (0.40–1.00)*
Place of living 0.462 0.822
 Urban vs. rural 0.81 (0.47–1.41) 0.95 (0.63–1.43)
CART initiation period 0.587 0.007
 1998–2002 vs. 2003–2007 0.86 (0.51–1.47) 1.83 (1.79–2.83)**
Risk group 0.085 0.851
 Non-MSM vs. MSM 1.63 (0.93–2.85) 0.96 (0.64–1.44)
Clinical AIDS concomitant or before CART 0.971 0.304
 No vs. yes 1.01 (0.58–1.75) 0.8 (0.52–1.22)
Nucleoside backbone 0.850 0.006
 ABC3TC vs. D4T3TC 0.69 (0.22–2.21) 0.21 (0.07–0.61)***
 ZDV3TC vs. D4T3TC 0.86 (0.47–1.58) 0.34 (0.19–0.63)***
 Other/none vs. D4T3TC 1.11 (0.45–2.73) 1.01 (0.50–2.04)***
Type of CART 0.013 0.012
2NRT + 1PI vs. 2NRT + 1NNRT 0.51 (0.29–0.90) 1.50 (1.02–2.20)#
 Other vs. 2NRT+ 1NNRT 1.98 (0.75–5.20) 2.83 (1.39–5.76)#
CD4 cell count/µL, per 100 cells 0.452 0.005
 CD4 cell count/µL 1.09 (0.87–1.37) 0.84 (0.75–0.95)
Viral load, log10 copies/mL 0.657 0.806
 <5 vs. ≥5 1.13 (0.65–1.98) 1.06 (0.69–1.63)
Hepatitis B surface antigen positivity 0.313 0.108
 No vs. yes 0.65 (0.28–1.51) 2.86 (0.79–10.27)
Hepatitis C antibody positivity 0.909 0.879
 No vs. yes 0.95 (0.42–2.17) 1.04 (0.62–1.74)
Table 3.  Crude analysis of factors related to toxicity drug modicifactions. Comparison of toxicity drug modifications to no drug 
modifications.
Analysis included the variable of interest, time, sequence and, if significant, the interaction of time with the variable of interest.
HR, hazard ratio, CI, confidence interval. ABC – abacavir; 3TC – lamivudine; D4T – stavudine; ZDV – zidovudine; NRT – nucleoside 
reverse-transcriptase inhibitor; NNRT – nonnucleoside reverse-transcriptase inhibitor; PI – protease inhibitor. * At month 18; ** at 
month 9; *** at month 6, p=0.004 for the comparison ABC3TC vs. D4T3TC, p<0.001 for the comparison ZDV3TC vs. D4T3TC, p=0.984 
for the comparison other/none vs. D4T3TC; # at month 12, p=0.020 for the comparison 2NRT+1PI vs. 2NRT+1NNRT, p=0.004 for the 
comparison other vs. 2NRT+1NNRT.
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in patients with no CART change compared to patients with 
switch-type only drug modifications.
Discussion
We found that CART modifications were frequent in Croatia; 
more than two-thirds of patients changed CART during the 
first 3 years of therapy. In the Eurosida study, which includ-
ed patients starting CART predominantly between 1999 and 
2002, 70% of patients remained on their original regimen at 
1 year after starting CART [3], whereas in our study only 50% 
(42% for the study period 1998–2002 and 54% in years 2003–
2007) were on the initial CART regiment after 1 year of ther-
apy. The 1-year probability of drug change in the Swiss co-
hort was 37% in CART-naïve patients starting therapy during 
1995–1998 and between 43.8% and 48.8% in the period 2000–
2005 [1]. Higher short-term CART modification rates have also 
been reported in vulnerable populations such as younger in-
dividuals, African-Americans, injection drug users, and pa-
tients lacking private health insurance [14]. In our study only 
5% of drug changes were due to virologic failure; hence, we 
confirmed previous findings from developed countries that 
the major cause for drug modifications is toxicity and not vi-
rologic failure [1–6,8,23]. In resource-limited settings, rates of 
drug modifications are lower and more frequently driven by 
virologic failure [24,25].
Thirty-nine percent of our patients had toxicity-related ADM 
during the first 3 years of CART; 25% had a change during the 
first year of follow-up. This is higher than in individuals from 
the Swiss cohort starting therapy between 2005 and 2008, in 
which 15.8% of individuals modified their treatment because 
of drug intolerance/toxicity during the first year of CART, [6] 
and is also higher than the 16% reported in the Eurosida cohort 
[3]. Data from the ICONA cohort from Italy, including patients 
starting therapy between 1997 and1999, found treatment dis-
continuation caused by toxicity in 21% of individuals [4]. The 
follow-up study from the same cohort included patients from 
1997 to 2007 and reported a probability of discontinuation be-
cause of intolerance/toxicity of 23.2% at 1-year of follow-up 
[5]. In resource-limited settings, ADM because of toxicity are 
less frequently done. For example, the cumulative probability 
of changes at 2 years due to toxicity in first-line regimens in 
Switzerland was 23.8%, compared to 11.7% in the townships 
of Khayelitsha and Gugulethu in Cape Town, South Africa [25].
Several observational studies have found that females have a 
higher toxicity rate of CART modifications than males [3–6,14]. 
Our findings were similar, but we also showed that there is 
 
Months of follow up
0 to 3 3 to 36
p-value HR (95% CI) 
Gender 0.002 0.870
 Female vs. Male 2.42 (1.39–4.24) 1.05 (0.59–1.88)
Age, per 10-year increase <0.001 0.188
 Age 1.42 (1.16–1.74) 1.13 (0.94–1.36)
Nucleoside backbone  0.69  
 ABC3TC vs. D4T3TC 0.56 (0.16–1.97) 0.23 (0.08–0.68)*
 ZDV3TC vs. D4T3TC 1.06 (0.58–1.95) 0.38 (0.20–0.72)*
 Other/none vs. D4T3TC 0.66 (0.21–2.11) 1.24 (0.49–3.10)*
Type of CART 0.061
 2NRT + 1PI vs. 2NRT + 1NNRT 0.60 (0.33–1.12) 1.49 (0.99–2.26)**
 Other vs. 2NRT+ 1NNRT  2.89 (0.77–10.81) 3.41 (0.95–12.28)**
Table 4. Multivariate analysis of factors related to toxicity drug modifications.
Adjusted for time sequence and in the 3 to 36 months follow-up model also for the CD4 cell count (not significant) and distance from 
HIV center (not significant). HR – hazard ratio; CI – confidence interval; ABC – abacavir; 3TC – lamivudine; D4T – stavudine; 
ZDV – zidovudine; NRT – nucleoside reverse-transcriptase inhibitor; NNRT – nonnucleoside reverse-transcriptase inhibitor; 
PI – protease inhibitor. * At month 6; p=0.008 for the comparison ABC3TC vs. D4T3TC, p=0.003 for the comparison ZDV3TC vs. D4T3TC, 
p=0.648 for the comparison other/none vs. D4T3TC. ** at month 15; p=0.06 for the comparison 2NRT+1PI vs. 2NRT+ 1NNRT, p=0.06 for 
the comparison other vs. 2NRT+1NNRT.
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a time-dependent effect and that the average hazard rate of 
treatment changes due to toxicity after 3-months on a partic-
ular CART regiment is similar in males and females. Regimens 
that contained ZDV or NVP were associated with higher risk of 
modification for toxicity reasons in women than in men, which 
is also in accordance with previous findings [26–29]. The ef-
fect of age on toxicity-related CART modifications has been 
examined in a number of studies, which have reported vari-
ous findings, possibly because of the diverse populations ana-
lyzed. A single-center study from London in 2001 showed that 
older patients were less likely to modify CART [30]. A study in 
vulnerable populations from Birmingham, Alabama, USA also 
found that younger age was a risk factor for treatment dis-
continuation due to non-gastrointestinal toxicity [14]. Similar 
to our findings, in the Swiss cohort older age was associated 
with higher risks of toxicity-related ADM during the first year 
of CART [6]. There have also been studies that did not find 
that age was a factor for toxicity-driven CART modifications 
[5]. In our study, older patients had a higher risk of treatment 
changes due to toxicity in the first 3 months on a particular 
CART regiment; however, afterwards the average hazard ratio 
of treatment changes due to toxicity was not associated with 
age (Tables 3 and 4).
Results of our study in the crude analysis suggest that patients 
who started CART with an NNRTI-based regimens compared 
to a PI-based regimen had a higher risk of treatment modifi-
cation within the first 3 months after CART initiation. This is 
in concordance with the adverse effects of EFV (central ner-
vous toxicity) and NVP (rash and hepatotoxicity), which typi-
cally occur more frequently at initiation of CART. After about 
12 months of therapy, patients on a PI-based regimen tend-
ed to have a higher risk of treatment change because of tox-
icity (Tables 3 and 4). PI-based regimens in our study popu-
lation were mainly the use of IND with or without ritonavir 
and LPV, and to a lesser extent nelfinavir. We were not able 
to find a difference between different nucleoside backbones 
during the first 3 months of therapy. However, afterwards, as 
expected, d4T use was associated with a higher toxicity rate 
compared to ABC and ZDV use.
The toxicity rates causing treatment modifications of individ-
ual antiretrovirals has not been widely reported. We found a 
toxicity rate in men for d4T and LPV modifications (32 events 
per 100 years of follow-up, and 4.7 events per 100 years of 
follow-up, respectively) similar to cohorts from Chelsea and 
Westminster in London (30.5 events per 100 years of follow-up 
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Figure 1.  Durability of first and subsequent 
antiretroviral drug combination 
therapy in patients starting therapy 
between 1998 and 2002 (A) and 2003 
to 2007 (B).
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and 4.7 events per 100 years of follow-up, respectively) [23]. 
The toxicity rate of drug modifications for other antiretrovirals 
(ABC, ddI, NVP, EFV) was somewhat higher in our study pop-
ulations. The largest difference was in the toxicity rate drug 
modifications due to ZDV, which was much more frequently 
changed in men from London (rate 22.7 per 100 years of fol-
low-up) compared to men from Croatia (5.1 per 100 years of 
follow-up). However, in the study from London, it could not 
be assessed whether patients switched ZDV because they 
actually had lipoatrophy or patients switched to prevent li-
poatrophy. Also, patients in Croatia are usually not switched 
if mild anemia is present, which might not have been the 
case in London.
Since the majority of patients in our study had a low baseline 
CD4 cell count and had generally advanced HIV infection, it is 
not surprising that patients who interrupted CART had worse 
virologic and immunologic outcomes compared to patients 
with no treatment modifications or switch-type modifications. 
When patients with no treatment modification were compared 
to patients with only switch-type modifications, we observed 
slightly better outcomes in patients with no treatment changes 
at 36 months of follow-up. However, because of the relatively 
small number of patients under study, we should be cautious 
in making a firm conclusion. Many switches and simplification 
strategies are available and are generally considered safe in 
virologically-suppressed individuals [31].
Our study has limitations. For example, the reason for ADM 
may be multifactorial, but we selected the one considered 
predominant. We investigated the toxic effects of CART by 
the occurrence of treatment modification, and some patients 
choose to stay on treatment despite adverse effects, so the 
true incidence of toxicities of a particular drug was not esti-
mated. Whether patients stop or change their CART may be 
influenced by the number and availability of drugs. Our study 
included only a few patients with a nucleoside backbone of 
TDF plus FTC, a backbone that is currently widely used in many 
countries. However, in southeastern European countries such 
as Croatia and Serbia, TDF and TDF plus FTC have been intro-
duced only after a long delay and are still not widely used. 
We used a repeated time-to-event analysis, which may pro-
vide more power and more efficient coefficients. However, set-
ting the follow-up time is challenging because out of 3 anti-
retroviral drugs used, only 1 is usually changed. The strength 
of this single-center clinic-based study is that all patients in 
Croatia were included and that the collected data were com-
plete, with almost no patients lost to follow-up.
Drug modifications
Group Time Interaction
Switch type only Interruption type None
CD4 cell count, per mm3
 Baseline  65 (27–196)  177.5 (38–246)  151 (63.5–217.5)
 12 months  266 (185–407)  276 (187–378)  363 (234–491) <0.001 <0.001 <0.001
 24 months  341 (226–443.5)  330 (213–439)  482.5 (326–639)
 36 months  369.5 (258–530)  291 (191–450)  480.5 (350–665.5)
Increase from baseline, 
CD4 cell count, per mm3
 12 months  173 (101–256)  138 (59–226)  189.5 (108–299)
 24 months  225.5 (146.5–335.5)  146 (38–283)  300 (179–459) <0.001 <0.001 <0.001
 36 months  281.5 (186–401)  138 (11–288)  329 (181–468.5)
Viral load,% <400 c/ml
 12 months  143/155 (92.3)  30/53 (56.6)  89/90 (98.9)
 24 months  143/152 (94.1)  37/53 (69.8)  81/82 (98.8) <0.001 0.159 0.179
 36 months  135/152 (88.8)  32/49 (65.3)  82/84 (97.6)
Table 5.  Virological and immunological outcomes 12, 24 and 36 months after initiation of combination antiretroviral therapy according 
to type of drug modifications.
Values are medians with interquartile ranges in parenthesis or number of patients with the characteristic/number analyzed and (%).
P-values are obtained by generalized estimating equation analysis.
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Conclusions
More and better-tolerated treatment options should be avail-
able and more frequently used in Croatia. In times when many 
national health insurance programs, especially those in mid-
dle-income countries, are concerned about the rising cost of 
treating increasing number of patients with HIV, we should 
keep in mind that older drug formulations are associated with 
higher toxicity rates.
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